SCHEMBL20657450

SCHEMBL20657450

C[N+](C)(C)CC(CC(=O)[O-])NC(=O)Nc1cccc(NS(=O)(=O)c2ccccc2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.45
▸ MEN1 O00255 2/20 0.45
▸ LMNA P02545 2/20 0.44
▸ PTGES O14684 1/20 0.44
▸ CPT2 P23786 1/20 0.43
▸ CPT1A P50416 1/20 0.43
▸ CPT1B Q92523 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ CRAT P43155 1/20 0.42
▸ GAA P10253 2/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ CA12 O43570 2/20 0.41
▸ CA1 P00915 2/20 0.41
▸ CA2 P00918 2/20 0.41
▸ CA9 Q16790 2/20 0.41
▸ GHSR Q92847 2/20 0.41
▸ MAPT P10636 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ ITGB3 P05106 1/20 0.41
▸ ITGAV P06756 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3690729 1.00 KMT2A (0.45) KMT2AMEN1LMNAPTGESCPT2
SCHEMBL13409952 0.92 PTGES (0.45) KMT2AMEN1LMNAPTGESKDM4E
SCHEMBL3688621 0.82 CPT2 (0.46) KMT2AMEN1CPT2CPT1ACPT1B
SCHEMBL3688624 0.82 CPT2 (0.46) KMT2AMEN1CPT2CPT1ACPT1B
SCHEMBL3680697 0.81 CPT2 (0.52) KMT2AMEN1LMNACPT2CPT1A
SCHEMBL3680702 0.81 CPT2 (0.52) KMT2AMEN1LMNACPT2CPT1A
SCHEMBL3693612 0.77 CPT2 (0.45) LMNACPT2CPT1ACPT1BCRAT
SCHEMBL3693608 0.77 CPT2 (0.45) LMNACPT2CPT1ACPT1BCRAT
SCHEMBL12010911 0.75 MAPT (0.65) KMT2AMEN1LMNAKDM4EGAA
SCHEMBL3689478 0.75 MAPK1 (0.56) CPT2CPT1ACPT1BCRATCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200129458-A1 COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS AJINOMOTO CO., INC. (JP) 2020-04-30 — — US claimed
EP-3438091-A1 COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS AJINOMOTO CO., INC. (JP) 2019-02-06 — — EP claimed
US-20190022039-A1 COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS AJINOMOTO CO., INC. (JP) 2019-01-24 — — US claimed
US-20200129458-A1 COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS AJINOMOTO CO., INC. (JP) 2020-04-30 — — US disclosed
EP-3438091-A1 COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS AJINOMOTO CO., INC. (JP) 2019-02-06 — — EP disclosed
US-20190022039-A1 COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS AJINOMOTO CO., INC. (JP) 2019-01-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200129458-A1 COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS GLP1R, GPR119, GIPR KMT2A 3732/4885MEN1 1833/4885LMNA 3342/4885
US-20190022039-A1 COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS GLP1R, GPR119, GIPR KMT2A 3732/4885MEN1 1833/4885LMNA 3342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback